Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.

Journal of viral hepatitis - 1 Mar 2020

Darvishian Maryam, Wong Stanley, Binka Mawuena, Yu Amanda, Ramji Alnoor, Yoshida Eric M, Wong Jason, Rossi Carmine, Butt Zahid A, Bartlett Sofia, Pearce Margo E, Samji Hasina, Cook Darrel, Alvarez Maria, Chong Mei, Tyndall Mark, Krajden Mel, Janjua Naveed Z

Abstract excerpt

Effectiveness of direct-acting antiviral (DAA) therapies could be influenced by patient characteristics such as comorbid conditions, which could lead to premature treatment discontinuation and/or irregular medical follow-ups. Here, we evaluate loss to follow-up and treatment effectiveness of sofosbuvir/ledipasvir ± ribavirin (SOF/LDV ± RBV), ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to British Columbia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Fluorenes

Share to Hepatitis C, Chronic

Share to Ribavirin

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Identifiers

PMID: 31664755
DOI: 10.1111/jvh.13228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.PMID 31664755Read ↗

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV eliminationSemantic proximity Read ↗

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Semantic proximity Read ↗

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy: A National Observational Cohort StudySemantic proximity Read ↗

The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).Semantic proximity Read ↗

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.Semantic proximity Read ↗

Ongoing Gaps in the Hepatitis C Care Cascade during the Direct-Acting Antiviral Era in a Large Retrospective Cohort in Canada: A Population-Based StudySemantic proximity Read ↗

The Role of Prior HBV Infection and Resistance Mutations on the Efficacy of 3TC/DTG as a Maintenance TherapySemantic proximity Read ↗

High rates of early treatment discontinuation in hepatitis C-infected US veterans.Semantic proximity Read ↗

Effect of sustained viral clearance on liver-related mortality among individuals living with hepatitis C by treatment era: a population-based retrospective cohort studySemantic proximity Read ↗

Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.Semantic proximity Read ↗

Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment.Semantic proximity Read ↗

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.